Rimegepant, Ubrogepant, and Lasmiditan in the Acute Treatment of Migraine Examining the Benefit-Risk Profile Using Number Needed to Treat/Harm

To develop and compare benefit-risk profiles for rimegepant, ubrogepant, and lasmiditan based on a network meta-analysis (NMA) of published clinical trials. METHODS: A fixed-effects Bayesian NMA of randomized controlled trials of lasmiditan, rimegepant, and ubrogepant for the acute treatment of adul...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnston, Karissa M, Powell, Lauren, Popoff, Evan, Harris, Linda, Croop, Robert, Coric, Vladimir, L’Italien, Gilbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555761/
https://www.ncbi.nlm.nih.gov/pubmed/36125279
http://dx.doi.org/10.1097/AJP.0000000000001072

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555761/
https://www.ncbi.nlm.nih.gov/pubmed/36125279
http://dx.doi.org/10.1097/AJP.0000000000001072

Ejemplares similares